Amgen recalls more than 900,000 bottles of Corlanor and Sensipar after foreign matter found on some tablets

Recall scope

Amgen has recalled more than 900,000 bottles of two prescription medicines, Corlanor and Sensipar, after finding unexpected foreign matter on some tablets. Reporting on the recall says the affected total is 944,142 bottles, and the action was described as a voluntary U.S. recall.

The medicines are used for serious chronic conditions. Corlanor, also known as ivabradine, is used for chronic heart failure. Sensipar, or cinacalcet hydrochloride, is used for conditions involving elevated calcium levels in chronic kidney disease and related parathyroid disorders.

What Amgen found

According to the reporting reviewed for this story, the issue was found during reserve-sample inspection. Amgen said the foreign matter was on the exterior surface of some tablets, over the coating, and treated the matter as a quality issue rather than a confirmed patient-harm event.

The company has described the recall as precautionary and said the potential health risk is low. No injuries or illnesses were reported in the material reviewed for this article.

Timeline and distribution

The affected products were distributed in the United States from October 28, 2021, through December 30, 2025. The recall covers multiple lot numbers and package sizes, with expiration dates extending into 2028.

Public reporting first surfaced on June 26, 2026, when EatingWell reported that the FDA recall covered 944,142 bottles and described it as a Class II recall. People published a separate report on June 27, 2026, and said the recall involved more than 900,000 bottles.

Both reports said the recall was announced through California pharmacy regulators. The reporting also indicates that the recall is nationwide in scope for the affected U.S. distribution.

Why the recall matters

The recall touches two drugs that many patients take chronically. That makes lot verification more important than it would be for a short-term medicine, because patients and pharmacies may need to sort out whether a bottle in use or in stock is part of the affected lots.

For people with heart failure or kidney-related disease, any interruption or confusion around medication supply can be disruptive even when the recall is precautionary. That is why public recall notices usually emphasize checking bottle labels, lot numbers, and package information against the official list.

What to check next

The available reporting does not include a full FDA enforcement entry in the material reviewed here, so the complete lot-by-lot list still matters for verification. Patients and pharmacies should compare bottles against the official recall notice before using or dispensing affected products.

Additional questions remain about whether regulators have posted a separate public entry with the full affected-lot breakdown and whether pharmacies have already begun contacting patients. For now, the key confirmed point is that Amgen has withdrawn the affected bottles as a precaution after finding foreign matter on some tablets.